Illustrative

Novo Nordisk sees pills capturing over third of GLP-1 market by 2030

Reuters·Jan 13

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Novo Nordisk anticipates that pills will account for more than a third of the GLP-1 market by 2030. This projection suggests a significant share of the market for pill form medications. The company's forecast indicates a notable presence of pills in the GLP-1 market in the future.

Full coverage

The Oral GLP-1 Tracker: Lilly’s Foundayo launch remains ‘muted’

Fierce Pharma·2d ago

Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030

Reuters·Jan 12

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

CNBC·Jan 10

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC·Jan 23

Obesity market sales potential tightens as Novo and Lilly enter new era

Yahoo Finance·Feb 2

View original report at Reuters ↗

Fetching the latest headlines…